Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from AstraZeneca ( (GB:AZN) ) is now available.
AstraZeneca announced that its RESOLUTE Phase III trial for Fasenra (benralizumab) in treating chronic obstructive pulmonary disease (COPD) did not meet the primary endpoint of statistical significance, despite showing numerical improvement. The trial’s safety and tolerability profile were consistent with known data, and the company plans to analyze the full data set for further insights. Fasenra is already approved for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis in multiple countries, and the results of this trial may impact its future applications and regulatory reviews.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £150.13 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call are the most significant factors contributing to its score. The technical analysis indicates a potential overbought condition, and the valuation suggests the stock is relatively expensive. Despite these concerns, the company’s robust pipeline and strategic initiatives support a positive outlook.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focusing on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The company’s innovative medicines are available in over 125 countries and are used by millions of patients worldwide.
Average Trading Volume: 2,258,963
Technical Sentiment Signal: Strong Buy
Current Market Cap: £176.9B
Learn more about AZN stock on TipRanks’ Stock Analysis page.